摘要
目的探讨乳腺癌TOPOⅡα、HER-2蛋白表达与蒽环类药物新辅助化疗疗效之间的关系。方法通过免疫组化(IHC)方法检测50例乳腺癌患者TOPOⅡα及HER-2蛋白的表达,分析TOPOⅡα和HER-2蛋白表达与临床病理疗效的关系、TOPOⅡα与HER-2表达的相关性及联合表达与临床病理疗效之间的关系。结果 50例乳腺癌患者中,TOPOⅡα蛋白表达17例,阳性率为34%(17/50),TOPOⅡα表达组的临床及病理有效率均优于TOPOⅡα未表达组(P<0.05)。TOPOⅡα与HER-2的表达具有相关性(P<0.05),HER-2及TOPOⅡα共同表达的病例为12例,但经相关性分析蒽环类药物新辅助化疗效果无明显差异(P>0.05)。结论乳腺癌组织中TOPOⅡα蛋白表达与HER-2蛋白表达具有相关性,TOPOⅡα蛋白表达对基于蒽环类药物的新辅助化疗的疗效预测有正相关作用。
Objective To investigate the protein expression of TOPO Ⅱ αand HER-2 gene in the prediction of anthracycline-based neoadjuvant chemotherapy in breast cancer. Methods Fifty cases of breast cancer patients were analyzed by immunohistochemistry（ IHC） for TOPOⅡα and HER-2 protein expression and the results were correlated to pathological and clinical responses. Results In the 50 cases,17 cases had TOPO Ⅱα protein expression（ 17 /50,34%）. The clinical and pathological efficiency in TOPOⅡα protein expression group was better than that of no TOPOⅡαprotein expression group（ P〈0. 05）. Twelve cases showed both of TOPOⅡαand HER-2 protein expression. TOPOⅡαprotein was corrected with HER-2 protein expression（ P〈0. 05）. However,the co-expression of TOPOⅡα and HER-2could not get benefit from anthracycline neoadjuvant chemotherapy. Conclusions The protein expression of TOPOⅡαwas highly correlated with HER-2 protein expression. The expression of TOPO Ⅱα correlates with pathological complete remission after anthracycline-based neoadjuvant chemotherapy.
出处
《诊断病理学杂志》
CSCD
2015年第1期38-40,44,共4页
Chinese Journal of Diagnostic Pathology
基金
广西卫生厅课题(Z2011224)
广西科技厅课题(2012GXNSFBA053115)
广西自然科学基金(2011GXNSFA018213)
